Posted by Michael Wonder on 17 Oct 2019
Foamix announces FDA acceptance of its new drug application for FMX103 minocycline foam for the treatment of moderate-to-severe papulopustular rosacea
17 October 2019 - PDUFA target action date of 2 June 2020
Foamix Pharmaceuticals today announced that the U.S. FDA has accepted for review the new drug application for FMX103 (minocycline topical foam 1.5%) topical foam.
Foamix is seeking approval of FMX103 for the treatment of moderate-to-severe papulopustular rosacea in adults.
